Literature DB >> 9379006

The PU.1 binding site is a cis-element that regulates pro-B/pre-B specificity of Vkappa-Jkappa joining.

R Hayashi1, T Takemori, M Kodama, M Suzuki, A Tsuboi, F Nagawa, H Sakano.   

Abstract

We have previously shown that the PU.1 binding motif (GAG GAA) in the 3'-enhancer region in the Ig kappa gene is responsible for the negative regulation of tissue (B/T)-specific Vkappa-Jkappa joining. Here we report that the PU.1 binding site also regulates the stage (pro-B/pre-B) specificity of Vkappa-Jkappa joining. In the substrate with base substitutions in the PU.1 binding motif, recombination took place in both pro-B (B220dull/CD43+) and pre-B (B220dull/CD43-) cells. In the transcriptional regulation, the PU.1 motif acts in a positive manner cooperatively with the nuclear factor-EM5 (or PIP) motif (GAAAAC), which is located 2 bp downstream from the PU.1 motif. Interestingly, base substitutions in the nuclear factor EM5 (PIP) motif did not affect the pro-B/pre-B specificity of Vkappa-Jkappa joining. Thus, the PU.1 motif regulates both temporal and tissue-specific rearrangements, while nuclear factor-EM5 is not involved in the regulation of Ig kappa recombination.

Mesh:

Substances:

Year:  1997        PMID: 9379006

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  BSAP can repress enhancer activity by targeting PU.1 function.

Authors:  S Maitra; M Atchison
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

2.  EBV-encoded LMP1 upregulates Igκ 3'enhancer activity and Igκ expression in nasopharyngeal cancer cells by activating the Ets-1 through ERKs signaling.

Authors:  Haidan Liu; Zhi Duan; Hui Zheng; Duosha Hu; Ming Li; Yongguang Tao; Ann M Bode; Zigang Dong; Ya Cao
Journal:  PLoS One       Date:  2012-03-01       Impact factor: 3.240

3.  Ras mediates effector pathways responsible for pre-B cell survival, which is essential for the developmental progression to the late pre-B cell stage.

Authors:  H Nagaoka; Y Takahashi; R Hayashi; T Nakamura; K Ishii; J Matsuda; A Ogura; Y Shirakata; H Karasuyama; T Sudo; S Nishikawa; T Tsubata; T Mizuochi; T Asano; H Sakano; T Takemori
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.